Amicus Therapeutics Inc (FOLD): Ellen Rosenberg , General Counsel & Corp. Secy of Amicus Therapeutics Inc purchased 15,000 shares on Jun 2, 2016. The Insider buying transaction was reported by the company on Jun 6, 2016 to the Securities and Exchange Commission. The shares were purchased at $7.67 per share for a total value of $115,050.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Nov 10, 2015, Margaret G Mcglynn (director) purchased 10,000 shares at $10.27 per share price.On Oct 5, 2015, Daphne Quimi (Vice President Finance) sold 11,250 shares at $13.13 per share price.Also, On Oct 5, 2015, Kenneth Peist (VP, Legal & IP) sold 10,000 shares at $13.14 per share price.On Sep 22, 2015, Bradley L Campbell (Chief Operating Officer) sold 13,001 shares at $16.78 per share price.
Shares of Amicus Therapeutics (FOLD) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.54 points or -7.00% at $7.17 with 31,26,208 shares getting traded. Post opening the session at $7.67, the shares hit an intraday low of $7.16 and an intraday high of $7.81 and the price vacillated in this range throughout the day. The company has a market cap of $911 M and the number of outstanding shares has been calculated to be 12,70,49,901 shares. The 52-week high of Amicus Therapeutics is $18.83 and the 52-week low is $4.985.
Company has been under the radar of several Street Analysts.Amicus Therapeutics is Initiated by BofA/Merrill to Buy and the brokerage firm has set the Price Target at $10. The Rating was issued on May 18, 2016.Amicus Therapeutics is Initiated by Robert W. Baird to Neutral and the brokerage firm has set the Price Target at $9. The Rating was issued on Apr 14, 2016.Amicus Therapeutics is Reiterated by Chardan Capital Markets to Buy and the brokerage firm has raised the Price Target to $ 15 from a previous price target of $10 .The Rating was issued on Apr 12, 2016.Amicus Therapeutics is Initiated by Goldman to Sell. The Rating was issued on Mar 30, 2016.
Amicus Therapeutics Inc. is a biopharmaceutical company. The Company focuses on the discovery development and commercialization of medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders (SDs). The Company’s lead product candidate is the pharmacological chaperone migalastat HCl (Galafold) a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Company’s development programs also include ERTs for LSDs including Fabry disease Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Company’s programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease SD-101 for Epidermolysis Bullosa (EB) as well as ERT products for Fabry disease Pompe disease and MPS I.